{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:34:53Z","timestamp":1792089293106,"version":"4.4.0"},"reference-count":47,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,9,8]]},"abstract":"<jats:title>Key Points<\/jats:title><jats:p>Anti-EBV TCR-like monoclonal antibodies reduce BLCLs tumor load in vivo. Anti-EBV TCR-like monoclonal antibodies mediate phagocytosis of BLCLs by macrophages.<\/jats:p>","DOI":"10.1182\/blood-2016-03-707836","type":"journal-article","created":{"date-parts":[[2016,6,25]],"date-time":"2016-06-25T15:00:25Z","timestamp":1466866825000},"page":"1396-1407","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":21,"title":["Targeting Epstein-Barr virus\u2013transformed B lymphoblastoid cells using antibodies with T-cell receptor\u2013like specificities"],"prefix":"10.1182","volume":"128","author":[{"given":"Junyun","family":"Lai","sequence":"first","affiliation":[{"name":"Immunology Programme, Life Sciences Institute,"},{"name":"Department of Microbiology and Immunology, Yong Loo Lin School of Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei Jian","family":"Tan","sequence":"additional","affiliation":[{"name":"Immunology Programme, Life Sciences Institute,"},{"name":"Department of Microbiology and Immunology, Yong Loo Lin School of Medicine,"},{"name":"Infectious Disease Interdisciplinary Research Group, Singapore-MIT Alliance for Research and Technology, National University of Singapore, Singapore;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien Tei","family":"Too","sequence":"additional","affiliation":[{"name":"Immunology Programme, Life Sciences Institute,"},{"name":"Department of Microbiology and Immunology, Yong Loo Lin School of Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna Ai Ling","family":"Choo","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, Yong Loo Lin School of Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan Hiong","family":"Wong","sequence":"additional","affiliation":[{"name":"Infectious Disease Interdisciplinary Research Group, Singapore-MIT Alliance for Research and Technology, National University of Singapore, Singapore;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatimah Bte","family":"Mustafa","sequence":"additional","affiliation":[{"name":"Immunology Programme, Life Sciences Institute,"},{"name":"Department of Microbiology and Immunology, Yong Loo Lin School of Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nalini","family":"Srinivasan","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, Yong Loo Lin School of Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angeline Pei Chiew","family":"Lim","sequence":"additional","affiliation":[{"name":"Defense Medical and Environmental Research Institute, Defense Science Organization National Laboratories, Singapore; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youjia","family":"Zhong","sequence":"additional","affiliation":[{"name":"Immunology Programme, Life Sciences Institute,"},{"name":"Department of Microbiology and Immunology, Yong Loo Lin School of Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas R. J.","family":"Gascoigne","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, Yong Loo Lin School of Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendon J.","family":"Hanson","sequence":"additional","affiliation":[{"name":"Defense Medical and Environmental Research Institute, Defense Science Organization National Laboratories, Singapore; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soh Ha","family":"Chan","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, Yong Loo Lin School of Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianzhu","family":"Chen","sequence":"additional","affiliation":[{"name":"Infectious Disease Interdisciplinary Research Group, Singapore-MIT Alliance for Research and Technology, National University of Singapore, Singapore;"},{"name":"Koch Institute for Integrative Cancer Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"MacAry","sequence":"additional","affiliation":[{"name":"Immunology Programme, Life Sciences Institute,"},{"name":"Department of Microbiology and Immunology, Yong Loo Lin School of Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"1","key":"2019111904443652500_B1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nri1526","article-title":"Cellular immunotherapy for viral infection after HSC transplantation.","volume":"5","author":"Moss","year":"2005","journal-title":"Nat Rev Immunol"},{"issue":"8","key":"2019111904443652500_B2","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1002\/cncr.21391","article-title":"Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation: results of a phase II trial.","volume":"104","author":"Blaes","year":"2005","journal-title":"Cancer"},{"issue":"8","key":"2019111904443652500_B3","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1182\/blood-2005-01-0377","article-title":"Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study.","volume":"107","author":"Choquet","year":"2006","journal-title":"Blood"},{"issue":"22","key":"2019111904443652500_B4","doi-asserted-by":"crossref","first-page":"e658","DOI":"10.1200\/JCO.2011.34.8656","article-title":"Successful treatment of a patient with Epstein-Barr virus-positive B-cell lymphoproliferative disorder resembling post-transplant lymphoproliferative disorder using single-agent rituximab.","volume":"29","author":"Maldonado","year":"2011","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111904443652500_B5","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1016\/j.ijid.2010.03.025","article-title":"Does rituximab increase the incidence of infectious complications? A narrative review.","volume":"15","author":"Kelesidis","year":"2011","journal-title":"Int J Infect Dis"},{"issue":"3","key":"2019111904443652500_B6","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1080\/10428190902730219","article-title":"Infectious complications of rituximab in patients with lymphoma during maintenance therapy: a systematic review and meta-analysis.","volume":"50","author":"Aksoy","year":"2009","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"2019111904443652500_B7","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1007\/s12032-011-9955-3","article-title":"Loss of CD20 antigen expression after rituximab therapy of CD20 positive B cell lymphoma (diffuse large B cell extranodal marginal zone lymphoma combination): a case report and review of the literature.","volume":"29","author":"Duman","year":"2012","journal-title":"Med Oncol"},{"issue":"6","key":"2019111904443652500_B8","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s12185-011-0870-3","article-title":"CD20-negative Epstein-Barr virus-associated post-transplant lymphoproliferative disease refractory to rituximab in a patient with severe aplastic anemia.","volume":"93","author":"Muramatsu","year":"2011","journal-title":"Int J Hematol"},{"issue":"3","key":"2019111904443652500_B9","doi-asserted-by":"crossref","first-page":"517","DOI":"10.3390\/antib2030517","article-title":"T-cell receptor-like antibodies: targeting the intracellular proteome therapeutic potential and clinical applications.","volume":"2","author":"Cohen","year":"2013","journal-title":"Antibodies (Basel)"},{"issue":"6","key":"2019111904443652500_B10","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.4049\/jimmunol.171.6.3064","article-title":"Tax and M1 peptide\/HLA-A2-specific Fabs and T cell receptors recognize nonidentical structural features on peptide\/HLA-A2 complexes.","volume":"171","author":"Biddison","year":"2003","journal-title":"J Immunol"},{"issue":"6","key":"2019111904443652500_B11","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1002\/eji.200939875","article-title":"Direct visualization of the dynamics of antigen presentation in human cells infected with cytomegalovirus revealed by antibodies mimicking TCR specificity.","volume":"40","author":"Makler","year":"2010","journal-title":"Eur J Immunol"},{"issue":"5","key":"2019111904443652500_B12","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1128\/JVI.01990-10","article-title":"Targeting hepatitis B virus-infected cells with a T-cell receptor-like antibody.","volume":"85","author":"Sastry","year":"2011","journal-title":"J Virol"},{"key":"2019111904443652500_B13","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1038\/srep03232","article-title":"Defining the expression hierarchy of latent T-cell epitopes in Epstein-Barr virus infection with TCR-like antibodies.","volume":"3","author":"Sim","year":"2013","journal-title":"Sci Rep"},{"key":"2019111904443652500_B14","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1017\/erm.2012.2","article-title":"T-cell-receptor-like antibodies - generation, function and applications.","volume":"14","author":"Dahan","year":"2012","journal-title":"Expert Rev Mol Med"},{"issue":"16","key":"2019111904443652500_B15","doi-asserted-by":"crossref","first-page":"4262","DOI":"10.1182\/blood-2010-07-299248","article-title":"An anti-PR1\/HLA-A2 T-cell receptor-like antibody mediates complement-dependent cytotoxicity against acute myeloid leukemia progenitor cells.","volume":"117","author":"Sergeeva","year":"2011","journal-title":"Blood"},{"key":"2019111904443652500_B16","author":"Dao"},{"issue":"4","key":"2019111904443652500_B17","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.4049\/jimmunol.0902414","article-title":"TCR mimic monoclonal antibody targets a specific peptide\/HLA class I complex and significantly impedes tumor growth in vivo using breast cancer models.","volume":"184","author":"Verma","year":"2010","journal-title":"J Immunol"},{"issue":"5","key":"2019111904443652500_B18","doi-asserted-by":"crossref","first-page":"3265","DOI":"10.4049\/jimmunol.1002376","article-title":"TCR mimic monoclonal antibodies induce apoptosis of tumor cells via immune effector-independent mechanisms.","volume":"186","author":"Verma","year":"2011","journal-title":"J Immunol"},{"issue":"3","key":"2019111904443652500_B19","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1093\/jnci\/djs521","article-title":"Antitumor activity of a monoclonal antibody targeting major histocompatibility complex class I-Her2 peptide complexes.","volume":"105","author":"Jain","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"2019111904443652500_B20","first-page":"195","article-title":"Studies of HIV infection and the development of Epstein-Barr virus-related B cell lymphomas following transfer of human lymphocytes to mice with severe combined immunodeficiency.","volume":"152","author":"Mosier","year":"1989","journal-title":"Curr Top Microbiol Immunol"},{"issue":"4","key":"2019111904443652500_B21","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1172\/JCI114573","article-title":"Epstein-Barr virus induces aggressive lymphoproliferative disorders of human B cell origin in SCID\/hu chimeric mice.","volume":"85","author":"Cannon","year":"1990","journal-title":"J Clin Invest"},{"key":"2019111904443652500_B22","first-page":"317","article-title":"EBV-associated B-cell lymphomas following transfer of human peripheral blood lymphocytes to mice with severe combined immune deficiency.","volume":"166","author":"Mosier","year":"1990","journal-title":"Curr Top Microbiol Immunol"},{"issue":"9","key":"2019111904443652500_B23","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1002\/jmv.22164","article-title":"Epstein-Barr virus, B cell lymphoproliferative disease, and SCID mice: modeling T cell immunotherapy in vivo.","volume":"83","author":"Johannessen","year":"2011","journal-title":"J Med Virol"},{"issue":"49","key":"2019111904443652500_B24","doi-asserted-by":"crossref","first-page":"13390","DOI":"10.1002\/anie.201406295","article-title":"Bioorthogonal cleavage and exchange of major histocompatibility complex ligands by employing azobenzene-containing peptides.","volume":"53","author":"Choo","year":"2014","journal-title":"Angew Chem Int Ed Engl"},{"key":"2019111904443652500_B25","first-page":"125","article-title":"Generation of lymphoblastoid cell lines (LCLs).","volume":"174","author":"Frisan","year":"2001","journal-title":"Methods Mol Biol"},{"key":"2019111904443652500_B26","author":"Tosato"},{"issue":"6","key":"2019111904443652500_B27","doi-asserted-by":"crossref","first-page":"4187","DOI":"10.4049\/jimmunol.177.6.4187","article-title":"Antibody targeting to a class I MHC-peptide epitope promotes tumor cell death.","volume":"177","author":"Wittman","year":"2006","journal-title":"J Immunol"},{"issue":"5","key":"2019111904443652500_B28","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1182\/blood.V84.5.1415.1415","article-title":"Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis.","volume":"84","author":"Koopman","year":"1994","journal-title":"Blood"},{"issue":"2","key":"2019111904443652500_B29","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1172\/JCI66776","article-title":"Macrophages eliminate circulating tumor cells after monoclonal antibody therapy.","volume":"124","author":"G\u00fcl","year":"2014","journal-title":"J Clin Invest"},{"issue":"7","key":"2019111904443652500_B30","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.4049\/jimmunol.148.7.2207","article-title":"Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages.","volume":"148","author":"Fadok","year":"1992","journal-title":"J Immunol"},{"issue":"2","key":"2019111904443652500_B31","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/sj.cdd.4400473","article-title":"Exposure of phosphatidylserine is a general feature in the phagocytosis of apoptotic lymphocytes by macrophages.","volume":"6","author":"Krahling","year":"1999","journal-title":"Cell Death Differ"},{"issue":"4","key":"2019111904443652500_B32","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/74704","article-title":"Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets.","volume":"6","author":"Clynes","year":"2000","journal-title":"Nat Med"},{"issue":"9","key":"2019111904443652500_B33","doi-asserted-by":"crossref","first-page":"6591","DOI":"10.1074\/jbc.M009483200","article-title":"High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R.","volume":"276","author":"Shields","year":"2001","journal-title":"J Biol Chem"},{"issue":"6","key":"2019111904443652500_B34","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.cell.2014.08.023","article-title":"Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity.","volume":"158","author":"Bournazos","year":"2014","journal-title":"Cell"},{"key":"2019111904443652500_B35","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1146\/annurev.immunol.21.120601.141036","article-title":"Molecular interactions mediating T cell antigen recognition.","volume":"21","author":"van der Merwe","year":"2003","journal-title":"Annu Rev Immunol"},{"issue":"11","key":"2019111904443652500_B36","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"},{"issue":"6533","key":"2019111904443652500_B37","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/375685a0","article-title":"Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1.","volume":"375","author":"Levitskaya","year":"1995","journal-title":"Nature"},{"issue":"23","key":"2019111904443652500_B38","doi-asserted-by":"crossref","first-page":"12616","DOI":"10.1073\/pnas.94.23.12616","article-title":"Inhibition of ubiquitin\/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1.","volume":"94","author":"Levitskaya","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"2019111904443652500_B39","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1084\/jem.20031219","article-title":"Evidence for the presentation of major histocompatibility complex class I-restricted Epstein-Barr virus nuclear antigen 1 peptides to CD8+ T lymphocytes.","volume":"199","author":"Voo","year":"2004","journal-title":"J Exp Med"},{"issue":"10","key":"2019111904443652500_B40","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1084\/jem.20040121","article-title":"CD8 T cell recognition of endogenously expressed epstein-barr virus nuclear antigen 1.","volume":"199","author":"Lee","year":"2004","journal-title":"J Exp Med"},{"issue":"10","key":"2019111904443652500_B41","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1084\/jem.20040191","article-title":"Endogenous presentation of CD8+ T cell epitopes from Epstein-Barr virus-encoded nuclear antigen 1.","volume":"199","author":"Tellam","year":"2004","journal-title":"J Exp Med"},{"issue":"19","key":"2019111904443652500_B42","doi-asserted-by":"crossref","first-page":"4002","DOI":"10.1182\/blood-2009-07-143545","article-title":"How I treat EBV lymphoproliferation.","volume":"114","author":"Heslop","year":"2009","journal-title":"Blood"},{"issue":"5","key":"2019111904443652500_B43","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nm0596-551","article-title":"Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes.","volume":"2","author":"Heslop","year":"1996","journal-title":"Nat Med"},{"issue":"5","key":"2019111904443652500_B44","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1182\/blood.V92.5.1549","article-title":"Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients.","volume":"92","author":"Rooney","year":"1998","journal-title":"Blood"},{"issue":"4","key":"2019111904443652500_B45","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2006-12-063008","article-title":"Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial.","volume":"110","author":"Haque","year":"2007","journal-title":"Blood"},{"issue":"5","key":"2019111904443652500_B46","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood-2009-08-239186","article-title":"Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients.","volume":"115","author":"Heslop","year":"2010","journal-title":"Blood"},{"issue":"11","key":"2019111904443652500_B47","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1182\/blood-2011-08-371971","article-title":"Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation.","volume":"119","author":"Doubrovina","year":"2012","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/128\/10\/1396\/1395172\/1396.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/128\/10\/1396\/1395172\/1396.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T00:51:06Z","timestamp":1692406266000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/128\/10\/1396\/35322\/Targeting-EpsteinBarr-virustransformed-B"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,8]]},"references-count":47,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,9,8]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2016-03-707836","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,8]]}}}